申请人:Vertex Pharmaceuticals Incorporated
公开号:US07053057B2
公开(公告)日:2006-05-30
This invention provides caspase inhibitors having the formula:
wherein Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CHN2, R, or —CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted C1-6 alkyl, F2, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0–2 heteroatoms. The compounds are useful for treating caspase-mediated diseases in mammals.
这项发明提供了具有以下公式的caspase抑制剂:其中环A是可选取代的哌啶,四氢喹啉或四氢异喹啉环;R1是氢,CHN2,R或—CH2Y;R是可选取代的基团,选自脂肪基团,芳香基团,芳基烷基团,杂环基团或杂环基烷基团;Y是电负性离去基团;R2是CO2H,CH2CO2H或其酯,酰胺或同分异构体;Ar是可选取代的芳基团;R3是氢,可选取代的C1-6烷基,F2,CN,芳基或R3附着在Ar上,形成0-2个杂原子的不饱和或部分饱和的五元或六元融合环。这些化合物在治疗哺乳动物的caspase介导的疾病方面是有用的。